ImmuCell Announces Change In Timing Of Anticipated FDA Submission; Says 'Planned To Make Our Next FDA Submission During Q2 Of This Year, We Have Decided To Add One Additional Month To The Projected Regulatory Development Process For Re-Tain'
Portfolio Pulse from Happy Mohamed
ImmuCell Corporation (ICCC) has announced a delay in its anticipated FDA submission for Re-Tain, pushing it back by one month. The company plans to use the extra time to optimize readiness for the related pre-approval re-inspection.
June 28, 2023 | 8:09 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
ImmuCell's FDA submission delay for Re-Tain could potentially impact the company's stock in the short term as investors may react to the news.
Delays in regulatory submissions can often be seen as negative news by investors, potentially leading to a short-term drop in the company's stock price. However, the impact may be mitigated if investors perceive the delay as a strategic move to ensure a smoother approval process.
CONFIDENCE 85
IMPORTANCE 75
RELEVANCE 100